Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Shares Outstanding (Diluted Average) (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $127.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) changed N/A year-over-year to $127.7 million, compared with a TTM value of $127.7 million through Dec 2025, changed N/A, and an annual FY2025 reading of $127.7 million, changed N/A over the prior year.
  • Shares Outstanding (Diluted Average) was $127.7 million for Q4 2025 at Cytek Biosciences, roughly flat from $127.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $138.7 million in Q3 2022 and bottomed at $35.9 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $122.8 million, with a median of $131.1 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 69.93% in 2022, then fell 3.49% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $81.5 million in 2021, then skyrocketed by 69.93% to $138.6 million in 2022, then fell by 2.37% to $135.3 million in 2023, then decreased by 3.08% to $131.1 million in 2024, then dropped by 2.57% to $127.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for CTKB at $127.7 million in Q4 2025, $127.5 million in Q3 2025, and $127.6 million in Q2 2025.